FMC Creighton Dialysis Llc is a medicare approved dialysis facility center in Findlay, Ohio and it has 14 dialysis stations. It is located in Hancock county at 1000 E Main Cross St Ste 102, Findlay, OH, 45840. You can reach out to the office of FMC Creighton Dialysis Llc at (419) 425-8515. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Creighton Dialysis Llc has the following ownership type - Profit. It was first certified by medicare in August, 2011. The medicare id for this facility is 362779 and it accepts patients under medicare ESRD program.
| Name | FMC Creighton Dialysis Llc |
|---|---|
| Location | 1000 E Main Cross St Ste 102, Findlay, Ohio |
| No. of Dialysis Stations | 14 |
| Medicare ID | 362779 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1000 E Main Cross St Ste 102, Findlay, Ohio, 45840 | |
| (419) 425-8515 | |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
| NPI Number | 1033409800 |
| Doing Business As | Creighton Dialysis Llc |
| Address | 1000 E Main Cross St Findlay, Ohio, 45840 |
| Phone Number | (419) 423-5184 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
| NPI Number | 1225582174 |
| Organization Name | Fresenius Kidney Care Creighton |
| Doing Business As | Fresenius Medical Care Creighton Dialysis, Llc |
| Address | 1000 E Main Cross St Findlay, Ohio, 45840 |
| Phone Number | (419) 423-5184 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
| NPI Number | 1598862971 |
| Organization Name | Creighton Dialysis Center |
| Doing Business As | Blanchard Valley Regional Health Center |
| Address | 1000 E Main Cross St Findlay, Ohio, 45840 |
| Phone Number | (419) 423-5184 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 41 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 58 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 552 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 8 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 56 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Creighton Dialysis Llc with elevated calcium levels.
| Patients with hypercalcemia | 70 |
| Hypercalcemia patient months | 670 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 73 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 38 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 57 |
| Patient months included in arterial venous fistula and catheter summaries | 501 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 53 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 15 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 63 |
| Hospitalization Rate in facility | 144.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 269.5 |
| Hospitalization Rate: Lower Confidence Limit | 80.6 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Creighton Dialysis Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 14.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 25.6 |
| Readmission Rate: Lower Confidence Limit | 7.4 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Creighton Dialysis Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .2 (Better than Expected) |
| SIR: Upper Confidence Limit | .97 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Creighton Dialysis Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 47 |
| Transfusion Rate in facility | 22.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 84.5 |
| Transfusion Rate: Lower Confidence Limit | 6.9 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Creighton Dialysis Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 314 |
| Mortality Rate in facility | 18.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.8 |
| Mortality Rate: Lower Confidence Limit | 14 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago
Blanchard Valley Dialysis Services, Llc Location: 1717 Medical Blvd # C, Findlay, Ohio, 45840 Phone: (419) 420-1633 |
FMC Creighton Dialysis Llc Location: 1000 E Main Cross St Ste 102, Findlay, Ohio, 45840 Phone: (419) 425-8515 |
News Archive
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a new molecular pathway that controls colorectal cancer development, and their exciting findings open new therapeutic opportunities.
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
› Verified 2 days ago